The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 05, 2024
Filed:
Apr. 29, 2021
Applicant:
Fundació Hospital Universitari Vall D'hebron - Institut DE Recerca, Barcelona, ES;
Inventors:
Rafael Simó Canonge, Sant Cugat del Vallès, ES;
Cristina Hernández Pascual, Barcelona, ES;
Assignee:
FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRON—INSTITUT DE RECERCA, Barcelona, ES;
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 9/08 (2006.01); A61K 31/00 (2006.01); A61K 31/155 (2006.01); A61K 31/40 (2006.01); A61K 31/403 (2006.01); A61K 31/4162 (2006.01); A61K 31/496 (2006.01); A61K 31/4985 (2006.01); A61K 31/513 (2006.01); A61K 31/519 (2006.01); A61K 31/522 (2006.01); A61K 38/26 (2006.01); A61K 45/06 (2006.01); A61K 47/02 (2006.01); A61P 27/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4985 (2013.01); A61K 9/0048 (2013.01); A61K 9/06 (2013.01); A61K 9/08 (2013.01); A61K 31/00 (2013.01); A61K 31/155 (2013.01); A61K 31/40 (2013.01); A61K 31/403 (2013.01); A61K 31/4162 (2013.01); A61K 31/496 (2013.01); A61K 31/513 (2013.01); A61K 31/519 (2013.01); A61K 31/522 (2013.01); A61K 38/26 (2013.01); A61K 45/06 (2013.01); A61K 47/02 (2013.01); A61P 27/06 (2018.01);
Abstract
The invention relates to dipeptidyl peptidase-4 inhibitors, including saxagliptin and sitagliptin, for use in the topical eye treatment and/or prevention of retinal neurodegenerative diseases, in particular diabetic retinopathy and its associated microvascular impairment. The invention also encompasses pharmaceutical topical eye compositions for use in the topical treatment and/or prevention of these diseases.